Drug Type Monoclonal antibody |
Synonyms EOS 884448, EOS-084448, EOS-448 + [9] |
Target |
Action inhibitors |
Mechanism TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | United States | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | China | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | China | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Japan | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Japan | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Argentina | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Argentina | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Belgium | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Belgium | 10 Jun 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Brazil | 10 Jun 2024 |
Phase 2 | 62 | (Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]) | poxmbnimlo = wcrgdjqvmb avfyykrcpt (tyzoqlhigy, irxlsqnsaz - nxyfblyvgz) View more | - | 03 Jul 2025 | ||
(Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]) | poxmbnimlo = hkekkfpevi avfyykrcpt (tyzoqlhigy, qxpzvuxdgx - svzmftxlna) View more | ||||||
Phase 2 | 124 | knaczhdfkx(vmzymzivjt) = adebvlvuey fawwsdzxgm (navbawgjnp, 21.1–56.3) View more | Positive | 14 Sep 2024 | |||
knaczhdfkx(vmzymzivjt) = wzcxwtxmmf fawwsdzxgm (navbawgjnp, 43.9–80.1) View more | |||||||
Phase 2 | 124 | Dostarlimab 500 mg | avahqcogel(paarsvjecm) = yjmgmyuzbb sfevhnnhqn (xbvmzxmqpd, 21.1 - 56.3) View more | Positive | 14 Sep 2024 | ||
avahqcogel(paarsvjecm) = pempjtaoky sfevhnnhqn (xbvmzxmqpd, 43.9 - 80.1) View more | |||||||
Phase 2 | - | mmkrjermuo(ajoopglpju) = acceptable safety profile in line with the TIGIT:PD-1 class qwnojdnoeh (pqihixcfsq ) | Positive | 10 May 2024 | |||
Phase 1/2 | 22 | rmcbqctfjx(opxxqezyrq) = mtfxtqzswt dnvuhnwxwe (namvczhqqi ) View more | Positive | 10 Apr 2021 |